All In Biotech

Drug Trial Radar · NCT04068597

Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies

An Open-label Phase I/IIa Study to Evaluate the Safety and Efficacy of CCS1477 as Monotherapy and in Combination in Patients With Advanced Haematological Malignancies.

Last checked: Nov 20, 2026Latest source record: Jun 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

250

Planned (sponsor's estimate)

Start

Aug 9, 2019

Primary completion

Mar 31, 2027

Study completion Mar 31, 2027

Sponsor

Lead sponsor
CellCentric Ltd.Industry
Sponsor type
Industry
First posted
Aug 28, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Phase 1/2a study to assess the safety, tolerability, PK and biological activity of CCS1477 (inobrodib) in patients with Non-Hodgkin Lymphoma, Multiple Myeloma, Acute Myeloid Leukaemia or High Risk Myelodysplastic syndrome.

Conditions

  • Haematological Malignancy
  • Acute Myeloid Leukemia
  • Non Hodgkin Lymphoma
  • Multiple Myeloma
  • Higher-risk Myelodysplastic Syndrome
  • Peripheral T Cell Lymphoma

Interventions

  • CCS1477Drug

    Oral capsule

  • PomalidomideDrug

    oral capsule

  • DexamethasoneDrug

    oral tablet

  • AzacitidineDrug

    Powder suspension for Injection

  • VenetoclaxDrug

    Oral tablet

  • BortezomibDrug

    Powder for solution for injection

  • IxazomibDrug

    Oral capsule

  • ElranatamabDrug

    Solution for injection

  • TeclistamabDrug

    Solution for injection

  • LenalidomideDrug

    Oral capsule

  • DaratumumabDrug

    Solution for injection, concentrate for solution for infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of treatment-related adverse eventsTime frame: Up to 12 months
  2. Incidence of laboratory abnormalitiesTime frame: Up to 12 months

Locations

39 sites in 5 countries. Site status is shown where the registry gives one.

  • Emory Winship Cancer Institute

    Atlanta, Georgia · Recruiting

  • Community Health Network

    Indianapolis, Indiana · Recruiting

  • The Center for Cancer and Blood Disorders (CCBD)

    Bethesda, Maryland · Recruiting

  • Nebraska Cancer Specialists

    Omaha, Nebraska · Recruiting

  • University of Nebraska Medical Center

    Omaha, Nebraska · Recruiting

  • Penn Medicine - Abramson Cancer Center Perelman

    Philadelphia, Pennsylvania · Recruiting

  • Institute Bergonie

    Bordeaux, France · Completed

  • Gustave Roussy

    Villejuif, France · Completed

  • Hospital Germans Trias i Pujol/ ICO Badalona

    Badalona, Spain · Recruiting

  • University Hospital Vall D'Hebron

    Barcelona, Spain · Completed

  • Hospital Clínic de Barcelona

    Barcelona, Spain · Recruiting

  • ICO L'Hospitalet (Instituto Catalán de Oncología)

    Barcelona, Spain · Recruiting

  • Hospital Universitario de La Princesa

    Madrid, Spain · Recruiting

  • Hospital Universitario Gregorio Marañón

    Madrid, Spain · Recruiting

  • Hospital Infanta Leonor

    Madrid, Spain · Recruiting

  • Hospital Universitario Ramón y Cajal

    Madrid, Spain · Recruiting

  • Hospital Universitario 12 de Octubre

    Madrid, Spain · Recruiting

  • CIOCC Hospital Universitario HM Sanchinarro

    Madrid, Spain · Completed

  • Universidad de Navarra

    Pamplona, Spain · Recruiting

  • Hospital Universitario y Politécnico La Fe de la Comunidad Valenciana

    Valencia, Spain · Recruiting

  • Karolinska Comprehensive Cancer Center

    Stockholm, Sweden · Completed

  • The Clatterbridge Cancer Centre NHS Foundation Trust,

    Bebington, United Kingdom · Recruiting

  • University Hospitals Bristol

    Bristol, United Kingdom · Recruiting

  • University Hospital of Wales

    Cardiff, United Kingdom · Recruiting

  • Royal Derby Hospital

    Derby, United Kingdom · Recruiting

  • Western General Hospital

    Edinburgh, United Kingdom · Recruiting

  • Gartnavel General Hospital

    Glasgow, United Kingdom · Recruiting

  • Leicester Royal Infirmary

    Leicester, United Kingdom · Recruiting

  • St Bartholomew's Hospital

    London, United Kingdom · Recruiting

  • Sarah Cannon Research Institute UK

    London, United Kingdom · Recruiting

  • NIHR University College London Clinical Research Facility

    London, United Kingdom · Recruiting

  • Imperial College

    London, United Kingdom · Recruiting

  • The Christie Hospital

    Manchester, United Kingdom · Recruiting

  • Newcastle upon Tyne Hospitals

    Newcastle upon Tyne, United Kingdom · Recruiting

  • Nottingham University Hospitals NHS Trust

    Nottingham, United Kingdom · Recruiting

  • Cancer and Haematology Centre

    Oxford, United Kingdom · Recruiting

  • University Hospital of Southampton

    Southampton, United Kingdom · Recruiting

  • Royal Stoke University Hospital

    Stoke-on-Trent, United Kingdom · Recruiting

  • The Royal Marsden

    Sutton, Surrey, United Kingdom · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.